

Note: This is Online Supplementary Document 1 of Samy W, Gaber OA, Amer RM, et al. Role of ACE2 and TMPRSS2 polymorphisms in clinical severity and outcomes of COVID-19 in Egypt. Afr J Lab Med. 2024;13(1), a2375. <https://doi.org/10.4102/ajlm.v13i1.2375>.

Table 1. Differences between mild/moderate and severe cases regarding demographic features, history of vaccination, co-morbidities, the occurrence of complications, and laboratory data

	Mild/Moderate	Severe	P
	N=49	N=51	
n(%)	n(%)		
Age (year)			
Mean ±SD	54.8±15.1	60.9±12.5	0.03
Range	(26-82)	(32-84)	
Gender			
Female (n=41)	23(46.9)	18(35.3)	0.3
Male (n=59)	26(53.1)	33(64.7)	
Smoking (n=36)	17(34.6%)	19(37.2%)	0.5
Comorbidities (n=56)	29(59.1%)	27(52.9%)	0.3
Vaccination (n=16)	7(14.3%)	9(17.6%)	0.4
Complications (n=36)	9(18.4%)	27(52.9%)	<0.001
Hemoglobin concentration (g/dl)			
Mean ±SD	13.0±1.7	12.4±2.4	0.2
Platelet count (10⁹/L)			
Mean ±SD	191±55	207±104	0.4
Total leukocytes count (10⁹/L)			
Median(range)	10.1(4-21)	10.1(1-29)	0.5
Lymphocytes count (10⁹/L)			
Median(range)	1.2(0.2-5.6)	1.1(0.2-5.0)	0.2
Neutrophils count (10⁹/L)			
Median(range)	8.9(2-16.5)	9(0.1-26.9)	0.4
Prothrombin time (sec)			
Median(range)	12.5(11-26)	13.1(11-21)	0.4
Urea (mg/dl)			
Median(range)	20.9(5-120)	29.0(7-169)	0.03
Creatinine (mg/dl)			
Median(range)	0.8(0.4-19.8)	1.0(0.4-9.1)	0.03
ALT (IU/L)			
Median(range)	27(10-171)	35(3-308)	0.8
AST (IU/L)			
Median(range)	31(12-174)	31(10-393)	0.6
LDH (U/L)			
Median(range)	391(171-1002)	389(111-1198)	0.2
Serum ferritin (ng/ml)			
Median(range)	351(32-2172)	530(27-3390)	0.07
CRP (mg/dl)			
Median(range)	44(2-345)	144(0-355)	<0.001
Cycle threshold (CT) value			
Median(range)	30.9(16.0-39.9)	28.1(17.5-39.9)	0.10

ALT: Alanine transaminase, AST: Aspartate aminotransferase, LDH: Lactate dehydrogenase, CRP: C Reactive Protein

Table 2. Differences between survived and died cases regarding demographic features and laboratory data

	Survived N=56 n(%)	Died N=44 n(%)	P
Age (year)			
Mean ±SD	56±14	60±14	0.2
Range			
Gender			
Female (n=41)	27	14	0.1
Male (n=59)	29	30	
Smoking (n=36)	17(30.3%)	19(43.2%)	0.4
Comorbidities (n=56)	34(60.7%)	22(50.0%)	0.2
Vaccination (n=16)	12(21.4%)	4(9.0%)	0.2
Complications (n=36)	15(26.7%)	21(47.7%)	0.02
Severity			
Mild/moderete (n=49)	44(78.5%)	5(11.4%)	<0.001
Severe (n=51)	12(21.4%)	39(88.6%)	
Hemoglobin concentration (g/dl)			
Mean ±SD	12.9±1.7	12.4±2.5	0.2
Platelet count (10⁹/L)			
Mean ±SD	195±68	204±101	0.5
Total leukocytes count (10⁹/L)			
Median(range)	10.0(4-20)	11.3(1-29)	0.2
Lymphocytes count (10⁹/L)			
Median(range)	1.0(0.2-5.6)	1.2(0.2-5.0)	0.5
Neutrophils count (10⁹/L)			
Median(range)	8.0(2-14.0)	9.5(0.1-26.9)	0.2
Prothrombin time (sec)			
Median(range)	12.5(11-26)	13.1(11-21)	0.1
Urea (mg/dl)			
Median(range)	22.5(5-120)	23.5(7-169)	0.3
Creatinine (mg/dl)			
Median(range)	0.9(0.4-19.8)	1.0(0.4-7.5)	0.08
ALT (IU/L)			
Median(range)	38(11-171)	30(3-308)	0.09
AST (IU/L)			
Median(range)	36(12-174)	28(10-393)	0.08
LDH (U/L)			
Median(range)	401(171-1198)	347(111-1129)	0.5
Serum ferritin (ng/ml)			
Median(range)	354(32-2167)	551(27-3390)	0.05
CRP (mg/dl)			
Median(range)	49(2-345)	106(0-355)	0.05
Cycle threshold (CT) value			
Median(range)	30.6(16.3-39.9)	28.2(16.0-39.9)	0.07